Skip to Main Content

Paper Details

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.
Nature
970
2020
1273, Betacoronavirus, Betacoronavirus spike proteins, CD8, CD8+, CD8+ T cell, COVID-19, D614G, SARS-CoV, SARS-CoV-, SARS-CoV-2, SARS-CoV-2 mRNA, SARS-CoV-2 spike protein, coronavirus disease, immunopathology, mRNA, mRNA vaccine, mRNA-1273, mice, severe acute respiratory syndrome coronavirus
Author NameAffiliation
Sarah R LeistUniversity of North Carolina at Chapel Hill
Alexandra Sch??ferUniversity of North Carolina at Chapel Hill
Stephen D SchmidtVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Lingshu WangVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Mark K LouderVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Ande WestUniversity of North Carolina at Chapel Hill
Laura J StevensVanderbilt University Medical Center
Nicole A Doria-RoseVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Guillaume B E Stewart-Jones
Jason S McLellanUniversity of Texas at Austin
Mark R DenisonVanderbilt University Medical Center
James D ChappellVanderbilt University Medical Center
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Ralph S BaricUniversity of North Carolina at Chapel Hill
Ralph S BaricUniversity of North Carolina at Chapel Hill
Ralph S BaricUniversity of North Carolina at Chapel Hill
Ralph S BaricUniversity of North Carolina at Chapel Hill
  • 1 - 17

Datasets